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Abstract
Overcoming intrinsic and acquired resistance of cancer stem/progenitor cells to current clinical treatments
represents a major challenge in treating and curing the most aggressive and metastatic cancers. This review
summarizes recent advances in our understanding of the cellular origin and molecular mechanisms at the
basis of cancer initiation and progression as well as the heterogeneity of cancers arising from the malignant
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transformation of adult stem/progenitor cells. We describe the critical functions provided by several growth
factor cascades, including epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor
(PDGFR), stem cell factor (SCF) receptor (KIT), hedgehog and Wnt/b-catenin signalling pathways that are
frequently activated in cancer progenitor cells and are involved in their sustained growth, survival, invasion and
drug resistance. Of therapeutic interest, we also discuss recent progress in the development of new drug combinations to treat the highly aggressive and metastatic cancers including refractory/relapsed leukaemias,
melanoma and head and neck, brain, lung, breast, ovary, prostate, pancreas and gastrointestinal cancers which
remain incurable in the clinics. The emphasis is on new therapeutic strategies consisting of molecular targeting
of distinct oncogenic signalling elements activated in the cancer progenitor cells and their local microenvironment
during cancer progression. These new targeted therapies should improve the efficacy of current therapeutic treatments against aggressive cancers, and thereby preventing disease relapse and enhancing patient survival.
Keywords: cancer progenitor cells • oncogenic signalling • endothelial progenitor cells •
chemotherapeutic treatments • drug resistance mechanisms • targeting therapies

Introduction
Major improvements in the treatment of cancer
patients have been accomplished in the few last
years. The development of more effective diagnostic
and prognostic methods is leading to an earlier therapeutic intervention in the clinics [1–17]. Among the
clinical treatments, tumour surgical ablation, hormonal therapy, radiotherapy and chemotherapy, alone or
in combination, are the most currently used therapies
for treating the patients diagnosed with diverse cancers including leukaemias and malignant solid
tumours, such as skin, head and neck, brain, lung,
kidney, bladder, prostate, breast, ovary, pancreas
and gastrointestinal cancers [1–3, 5–9, 12–24]. In
general, the patients diagnosed with localized cancers that are treated with these conventional clinical
therapies have a high response rate and a good outcome. Although these conventional therapies are
effective in initial phase of treatment, the cancer progression to locally invasive and metastatic states is
often associated with resistance to treatments and
disease relapse, which leads to the death of the
patients [1–3, 5–7, 9, 12, 13, 15–17, 21–23, 25–31].
The cancer recurrence phenomenon has been associated with the accumulating genetic and/or epigenic
alterations in cancer cells that may contribute to
their uncontrolled growth, survival and invasion as
well as their intrinsic or acquired resistance to
clinical treatments [1–3, 13, 16, 26–28, 31–41].
The altered activation and/or overexpression of
numerous growth factors, adenosine 59-triphosphate
(ATP)-binding cassette (ABC) multidrug efflux transporters, anti-apoptotic factors (MYC, Bcl-2, NF-kB
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and survivin) as well as a decreased expression or
activity of tumour suppressor genes (p53 and phosphatase and tensin homolog, PTEN) in cancer cells
may contribute to the drug resistance and disease
relapse [1, 16, 26–28, 32–46].
Recently, new concepts have been proposed on
the critical implication of highly leukaemic or
tumourigenic cancer progenitor cells also designated as cancer stem cells or cancer-initiating cells, in
cancer initiation and progression to metastatic disease states and resistance to conventional therapies [16, 35, 39, 40, 47–53]. These cancer progenitor cell-based concepts may partially explain the
recurrence of the most aggressive cancers to current clinical treatments. More specifically, the reactivation of diverse developmental signalling cascades
(epidermal growth factor (EGF)/EGFR, stem cell
factor (SCF)/KIT, platelet-derived growth factor
(PDGF)/PDGFR, sonic hedgehog (SHH/PTCH/GLI
transcription factor) and/or Wnt/b-catenin) combined
with the increased DNA repair mechanisms and
ABC transporter-mediated multi-drug efflux in cancer progenitor cells may be responsible, at least in
part, for their resistance to current clinical therapies
[13, 16, 30, 31, 35–37, 39–42, 46, 54–61].
Moreover, the changes in the local microenvironment of cancer progenitor cells may also influence
their behaviour. In this review, we discuss the importance of considering new concepts on the implication
of cancer progenitor cells in cancer development in
order to overcoming resistance to conventional cancer therapies. The emphasis is on the oncogenic
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Fig. 1 Scheme showing the critical functions assumed by cancer progenitor cells and the bone-marrow derived
circulating cells in the development of leukaemias, sarcomas, brain tumours and various epithelial cancers. The accumulating genetic alterations in haematopoietic stem cells (HSCs) and/or lymphoid or myeloid precursors, which may lead to
the development of leukaemias, are shown. Moreover, the genetic alteration in the embryonic hemangioblast or neuroectodermal stem cell-derived progeny, which may lead to their persistence in adult life and subsequent hemangioblastoma or
neuroectodermal tumour formation, is also indicated. The genetic or epigenic alterations in neural stem cells (NSCs) and/or
neuronal and glial cell lineage precursors, whose molecular events may result in their malignant transformation into brain
tumour stem cells (BTSCs) and the generation of malignant neuronal and glial cell lineage precursors, are also shown. In
addition, the implication of tissue-specific adult stem cells and reactive stromal host cells including the activated fibroblasts,
immune cells and bone-marrow-derived endothelial progenitor cells (EPCs) in the tumour neovascularization is also illustrated. Abbreviations: LSC, leukaemic stem cell; MMPs, matrix metalloproteinases; MPS, mesodermal progenitor cells;
MSC, mesenchymal stem cell; SDF-1, stromal cell-derived factor-1; uPA, urokinase type plasminogen-activator.

events occurring frequently in cancer progenitor
cells and their local microenvironment during cancer progression and the molecular mechanisms
involved in their resistance to current chemotherapeutic drugs. Furthermore, we also discuss the
beneficial effects of targeting different intracellular
signal transduction pathways in cancer progenitor
cells and their microenvironment for the development of more effective therapeutic treatments against
the most aggressive and recurrent cancers.

Functions of cancer progenitor
cells in the cancer initiation
and progression
New model of carcinogenesis based on
the cancer progenitor cells
Numerous investigations have provided evidence
that the genetic and/or epigenic alterations occurring
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Fig. 2 Scheme showing the possible oncogenic cascades involved in the stimulation of sustained growth, survival,
migration and drug resistance of cancer progenitor cells. The intracellular elements induced through the activation of
EGF-EGFR, PDGF/PDGFR, SCF/KIT, hedgehog (SHH/PTCH/GLI), Notch and Wnt/b-catenin signalling and possible
cross-talks between these cascades are shown. The changes in the expression levels of numerous target gene products, including down-regulated E-cadherin and up-regulated matrix metalloproteinases (MMPs), urokinase plasminogen activator (uPA) and vascular endothelial growth factor (VEGF), which can contribute both to the malignant transformation of cancer progenitor cells during cancer progression and angiogenesis, are also indicated. Furthermore, the
effects of pharmacological agents acting as the potent inhibitors of the oncogenic cascades including the selective
inhibitors of EGF-EGFR system (gefitinib and erlotinib), smoothened hedgehog signalling element (cyclopamine),
Notch (g-secretase inhibitor) as well as Wnt/b-catenin cascades (monoclonal anti-Wnt antibody ‘mAb’) on the cancer
cells are also indicated. Abbreviations: APC, adenomatous polyposis coli; ABCG2/BCRP-1, brain cancer resistence
protein-1; CDK, cyclin-dependent kinase; CoA, co-activators; COX-2, cyclooxygenase-2; Dsh, Dishevelled; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; Fzd, Frizzled receptor, GSKb, glycogen synthase
kinaseb; ICN, intracellular domain of Notch; IkBa, inhibitor of nuclear factor-kBa; KIT, stem cell factor receptor; LEF,
lymphocyte enhancer factor; LPR, lipoprotein co-receptor; MAPKs, mitogen-activated protein kinases; MEK, extracellular signal-related kinase kinase; NF-kB, nuclear factor-kB; PI3K, phosphatidylinositol-3’ kinase; PTEN, tensin homologue deleted on chromosome 10; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor-receptor; PLC-g, phospholipase C-g; PTCH, hedgehog-patched receptor; SCF, stem cell factor; SHH, sonic hedgehog ligand; SMO, smoothened; TCL, T-cell factor; WIF-1, Wnt-inhibitory factor-1; Wnt, Wingless ligand.
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Table 1 Characterization of specific biomarkers and functional properties of human cancer progenitor cells isolated
from diverse malignant tissues and cancer cell lines
Malignant Tissue/ Established cancer cell line

Specific biomarkers/Stem cell-like properties

Hematological malignancy
Acute myeloid leukemia (AML)

CD34 /CD38 , Thy21 , KIT , Leukaemic grafts in vivo

Multiple myeloma and RPMI 8226 and NCI-H929
myeloma cells

CD138 , Leukaemic grafts in vivo

1

2

2

2

2

Pediatric brain tumor
Primary medulloblastoma, astrocytoma, glioblastoma
multiforme and ependymoma

CD133 /nestin , Neurospheres, Tumorigenic in vivo

Primary ganglioglioma

CD133 /nestin , Neurospheres

1

1

1

1

1

1

Adult brain tumor
Primary glioblastoma multiforme

CD133 /nestin , Neurospheres, Tumorigenic in vivo

Melanoma
Metastatic melanoma

CD20 , Melanoma spheroids

Primary WM115 melanoma cell line

CD20 , Melanoma spheroids

Metastatic WM239A melanoma cell line

CD20 , Melanoma spheroids

1
1
1

Breast cancer
Primary and metastatic breast cancers
MCF-7 breast cancer cell line

1

2/low

, Oct-3/4, Mammospheres, Tumorigenic in vivo

CD44 /CD24
1

2/low

CD44 /CD24

, Mammospheres, Tumorigenic in vivo

Ovarian cancer
A2 clone from primary ovarian cancer

CD44 , Oct-3/4, Nanog, EGFR, Vimentin, E-cadherin
Tumorigenic in vivo

A4-T spontaneously transformed clone

CD44 , Oct-3/4, Nanog, EGFR, Vimentin/Snail,
Tumorigenic in vivo, A4-T > A2 clone

1

1

Prostatic cancer
Primary and metastatic prostatic adenocarcinomas

high

1

1

high

1

/SMO /b-catenin, Tumorigenic in vivo

high

/ CD133

CD133 /CD44 /a2b1-integrin

LAPC-4, LAPC-9 and DU 145 prostatic cancer cell
lines or xenografts

CD44

PC3 prostatic cancer cell line

CD44

, Prostatespheres

1

Pancreatic cancer
Primary pancreatic adenocarcinoma

CD441/CD241/ESA1, Tumorigenic in vivo

PancTuI and A81 8-6 pancreatic cancer cell line

CD133 /ABCG2

1

1

Colorectal cancer
Colorectal adenocarcinoma

1

CD133 , colon spheres, Tumorigenic in vivo

Head and neck cancer
Head and neck squamous cell carcinoma

CD441, Tumorigenic in vivo

ABCG2/BCRP, breast cancer resistance protein; ESA, epithelial-specific antigen.
© 2007 The Authors
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in the multi-potent tissue-specific adult stem cells
and/or their early progenies may lead to their malignant transformation into cancer progenitor cells also
designated as cancer stem cells or cancer-initiating
cells (Fig. 1 and 2) [3, 13, 37, 39–41, 47–53, 55, 57,
60, 62–65]. A small population of undifferentiated- or
poorly differentiated cancer progenitor cells, which
possesses the stem cell-like properties including
their self-renewal ability and capacity to give rise to
the bulk mass of further differentiated malignant
cells, appears to represent the principal cancer cells
that are responsible for leukaemia or tumour formation [13, 39, 40, 47, 59, 63, 66–76]. Accumulating
genetic and/or epigenic alterations in leukaemic or
tumourigenic cancer progenitor cells occurring during cancer progression, and more particularly the
acquisition of a migratory phenotype by tumour cells
during epithelial-mesenchymal transition (EMT) program, may also confer to them the invasive properties that are essential for their migration to distant
metastatic sites [39, 40, 49, 64, 72, 73, 77–81]. This
cancer progenitor cell model of carcinogenesis is
notably supported by the fact that the poorly differentiated and highly-leukaemic or tumourigenic cancer
progenitor cells isolated from patients’ malignant tissue specimens may give rise to the bulk mass of further differentiated cancer cells ex vitro and in vivo, and
thereby be responsible for leukaemia or tumour development (Fig. 1; Table 1, 2) [47, 63, 66–70, 72, 73, 75, 76].
Recent investigations have also revealed that a very
small sub-population of cancer progenitor cells with
stem cell-like properties may be isolated from wellestablished cancer cell lines and maintained under
an undifferentiated or poorly differentiated state during
long years in culture, and this even after multiple passages in medium containing serum [47, 59, 65–69, 72,
73, 75, 76, 82–84]. In regard with this, we describe here
the recent investigations that have led to the isolation of
cancer progenitor cells from numerous cancer types
and the establishment of their functional properties
ex vitro and in animal models in vivo.

Isolation and ex vitro and in vivo characterization
of functional properties of cancer progenitor cells
Significant advancements have been made in the
identification of the specific biomarkers of multipotent tissue-specific adult stem cells. Researchers
have been able to isolate these adult stem cells as
well as their malignant counterparts, cancer progen986

itor cells from total cell mass in cancer patients’
malignant tissue specimens and well-established
cancer cell lines for their ex vitro and in vivo functional
characterization (Table 1, 2) [47, 59, 65–69, 71–73,
75, 76, 82–89]. Among the methods that are frequently used for the enrichment and isolation of very
small population of cancer progenitor cells with stem
cell-like properties, there are the fluorescence-activated cell sorting (FACS), using the specific antibodies directed against one or several stem cell-like surface markers, such as CD34, CD138, CD20, CD133
and/or CD44 and the Hoechst dye efflux technique
[47, 59, 65–69, 71–73, 75, 76, 82–89]. Hence, the
isolated small sub-population of cancer progenitor
cells may be subsequently expanded ex vivo in
serum-free medium and further characterized by the
non-adherent spheroid generation and clonogenicity
assays for establishing their self-renewal and multilineage capacities in vitro. The implantation and serial transplantations assays may also be carried out
with the isolated cancer progenitor cells in animal
models for estimating their leukaemic or tumourigenic potential and self-renewal ability in vivo [47, 59,
65–69, 71–73, 75, 76, 82–87]. More particularly, a
very small sub-population of human cancer progenitor cells expressing the specific stem cell-like surface
markers has been successfully isolated from malignant tissues and/or well-established cancer cell lines.
Among the cancer types harbouring a sub-population of cancer progenitor cells, there are the acute
myeloid leukaemia, multiple myeloma, melanoma,
head and neck, brain, breast, ovary, prostate, pancreas and colorectal cancers (Table 1) [47, 66–69,
71–73, 75, 76, 82–87, 90–92]. It has been shown that
all these cancer progenitor cells, which possess a
self-renewal capacity, are able to give rise in vitro
and/or in vivo to the bulk mass of further differentiated cancer cells that recapitulates the cellular heterogeneity and morphological characteristics of cancer
tissues from which they originate [66–69, 71–73, 75,
76, 82–84, 86]. The fact that the engrafted leukaemic
or tumourigenic cells could be serially transplanted
into other mice has also provided further experimental evidence of the self-renewal capacity of these
cancer-initiating cells [67–69,73,76]. Particularly, a
small number of these poorly differentiated cancer
progenitor cells showed a higher leukaemic or
tumourigenic potential in animal models in vivo as
compared to their further differentiated progenies
[67–69, 72, 75, 76, 83, 84, 86, 87]. For instance, a

© 2007 The Authors
Journal compilation © 2007 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

J. Cell. Mol. Med. Vol 11, No 5, 2007
Table 2 Characterization of specific biomarkers and functional properties of Hoechst dye-low side population of cells
isolated from diverse malignant tissues and cancer cell lines
Malignant Tissue/Established cancer cell line
Leukemia
Acute myeloid leukemia (AML) cells
from bone marrow
Lung cancer
Patients' non-small cell lung cancer tissues
Human small-cell carcinoma NCI-H146
and NCL-H345 cell lines
Human A549*, H460*, H23, HTB58, H441*
and H-2170 lung carcinoma cell lines
Brain cancer
Patients' primary neuroblastoma tissues
Human JF, SK-N-SH, IMR32, LAN-1, LAN-5
and rat B104 neuroblastoma cell lines
Human (D54, U87, U251, U373*, HS 683)
glioma cell lines
Rat (C6) glioma cell line
Melanoma
Metastatic melanoma DM1N, DM2N, and
DM3N cell lines from lymph node metastases
Breast cancer
Patients' primary breast cancer tissues
Human breast *MCF-7 and
SK-BR-3 cancer cell lines
Ovarian cancer
Patients' primary ascite cells
Human (IGROV-1, SK-OV-3, OVCAR-3, PA-1)
and mouse (*MOVCAR 7 and 4306)
ovarian cancer cell lines
Prostatic cancer
Human LAPC-9 cell-tumor xenograft
Human primary RWPE-2 and metastatic
DU145 and PC3 prostate cancer cell lines
Gastrointestinal cancers
Human *HuH7, Hep3B and PLC/PRF/5
hepatocellular cancer cell lines
Human WiDr, CCK81, Colo201, Colo205,
SW480 and HSC15 colorectal cancer cell lines,
Human esophageal TE1, TE2 and TE13 and
gastric NUGC3, MKNI, MKN7 and MKN28
cancer cell lines
Pancreatic cancer
Human CD18 pancreatic cancer cell line
Human PK9 and PK45H pancreatic cancer cell lines
Retinal cancer
Mouse retinoblastoma
Human WERI-Rb27 retinoblastoma cell line
Cervix cancer
HeLa cancer cell line
Thyroid cancer
Human anaplastic (*ARO and FRO) and
papillary (NPA) thyroid cancer cell lines
WRO follicular carcinoma cell line
Head and neck sqamous cell carcinoma
Human metastatic UMSCC10B and
HN12 cell lines
Nasopharyngeal carcinoma
Human CNE-1, CNE-2*, SUNE-1,
HONE-1 and C-666-1 cell lines
Hepatocellular carcinoma
Human *Huh7 and *PLC/PRF/5
liver cancer cell lines

Specific biomarker/ Stem cell-like property
CD342/low
Leukaemic grafts in vivo

ABCG2, MDR1, MPR1,
Verapamil-, fumitremorgin C- or reserpinesensitive, *Tumorigenic in vivo
GD2 ganglioside, KIT+/CD71-/low/CD56-/low
CD133-/low, ABCG2, ABCA3
ABCG2, ABCA3 (JF/IMR32)
Verapamil-sensitive
*
Tumorigenic in vivo
BCRP-1, MDR1, Tumorigenic in vivo
Nestin, gp100
Verapamil-sensitive
ABCG2, Notch-1, b-catenin
*Verapamil sensitive*, Tumorigenic in vivo
ABCG2, Verapamil-sensitive
ABCG2/BCRP-1, Verapamil-sensitive*, Tumorigenic in vivo

Tumorigenic in vivo
Verapamil sensitive
*GATA 6/CK14/CD133, *BMP2, *JAG1
*ABCG2, *ABCB1, *CEACAM6, *AREG,

Verapamil sensitive
ABCG2, Verapamil-sensitive
ABCG2, Verapamil-sensitive

Verapamil-sensitive,
*Tumorigenic in vivo
Verapamil-sensitive
CK19+, SMO+, Verapamil-sensitive
*Tumorigenic in vivo
AFP+/CK19+, *ABCG1 and ABCF2 or
*ABCB2, ABCC7, ABCA5, ABCB1,
*Wnt ligands and FZD7,
Verapamil-sensitive, Tumorigenic in vivo

BCRP-1/ABCG2, breast cancer resistance protein-1; BMP2, bone morphogenetic protein 2; CEACAM6, carcinoembryonic
antigen-related cell adhesion molecule; MDR1, multidrug resistance 1 gene, MPR1, multidrug resistant associated protein 1.
© 2007 The Authors
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sub-population of non-adherent melanoma spheroid
cells expressing CD20+ antigen has been isolated
from human metastatic melanoma tissues and established primary WM115 and metastatic WM239A
melanoma cell lines derived from a same patient
[70]. The multi-potent individual cells within these
non-adherent melanoma spheres established from
metastatic melanoma tissues were able to give rise
to multiple mesenchymal cell lineages including
melanocytes, adipocytes, osteocytes and chondrocytes
ex vitro and in vivo (Table 1) [70]. These cells forming
non-adherent melanoma spheres were also more
tumourigenic than their adherent melanoma cell
counterpart in severe combined immunodeficient
(SCID) mice in vivo [70]. Similarly, a single clone (A2)
expressing different markers, such as CD44, Oct-3/4,
Nanog, EGFR, vimentin and E-cadherin and able to
form the multi-layered spheroids ex vivo, has been
isolated from the total cancer cell population of the
ascites of a patient with advanced ovarian cancer
[63]. Additionally, another clone A4-T derived from
multi-layered spheroids that underwent a spontaneous transformation in culture has also been isolated. A4-T was characterized by an expression marker
profile comparable to that of A2 clone with the exception that it expressed a detectable level of the transcriptional repressor of E-cadherin, Snail but not
E-cadherin suggesting that this clone may have to
undergo a more complete EMT program [63].
Importantly, the A4-T clone was more potential than
the A2 clone to form the tumours with an architecture
resembling to the patients’ original tumours, and
undergo metastases in nude mice in vivo (Table 1)
[63]. On the other hand, by using a specific antibody
directed against the embryonic stem cell-like marker
Oct-3/4, which is a POU family transcription factor,
combined with the analyses of its expression level by
RT-PCR, it has been observed that the human
breast, liver, pancreas, kidney, mesenchymal and
gastric adult stem cells, and a few keratinocytes in
the basal layer of human skin epidermis express significant levels of Oct-3/4 [93]. Moreover, the human,
dog and rat tumours and HeLa and MCF-7 cancer
cell lines also expressed a detectable level of its
stem cell-related marker Oct-3/4, while the differentiated cells did not, supporting thereby the cancer progenitor cell concept of tumourigenesis [93].
In addition, the enrichment of undifferentiated or
poorly differentiated cancer progenitor cells expressing the stemness genes from patient’s cancer sam988

ples or well-established cancer cell lines has also
been performed by the Hoechst dye efflux technique,
which is particularly useful when the tissue-specific
stem cell markers are not well established. Hence, a
very small fraction of cancer cells designated as a
‘side population’ (SP), and which possesses a high
ability to actively efflux the fluorescent DNA-binding
dye, Hoechst 33342 due to elevated expression levels of ABC multi-drug efflux pumps, has been identified in several mammalian malignant tumour tissues
and well-established cancer cell lines (Table 2) [54,
74, 75, 86–89, 94–105]. It has been observed that a
small number of SP cells may generate both SP and
non-SP cells in culture ex vivo or in vitro by asymmetric division and are able to induce the leukaemia-like
disease or tumour formation in animal models in vivo
resembling to the patients’ original cancers [54,
74–76, 80, 86–89, 94, 96–98, 101, 103]. For instance,
the FACS sorted SP fraction from the C6 glioma cell
line may differentiate in vitro and in vivo into neurons
and glia expressing the neuronal (low molecular
weight neurofilament [NF-L] or bIII-tubulin) and glial
(glial fibrillary acidic protein, [GFAP]) markers,
respectively, and form the metastatic tumours when
injected intraperitonally in nude mice in vivo [96,97].
Importantly, it has been noted that the number of
cancer cells detected in the SP population versus the
non-SP fraction may be significantly influenced
by the experimental conditions including the
source of the patients’ malignant tissues (untreated,
treated and/or relapsed patients) and the culture
conditions used (cell density and growth factors) [54,
97, 102, 105].
In light of these observations, it appears that several types of malignant tissues and well-established
cancer cell lines contain a very small population of
undifferentiated or poorly differentiated cancer progenitor cells that may be responsible for the generation of leukaemia or tumour formation in animal models in vivo. Hence, the most aggressive human cancers may originate from this small highly leukaemic
or tumourigenic cancer progenitor cell sub-population possessing stem cell-like properties and an
aberrant differentiating ability. Based on these observations, it appears important to consider the presence of these putative cancer progenitor cells in
certain cancer cell lines which have been initially
established from patients with leukaemia and malignant
primary or secondary neoplasms. More particularly,
this small sub-population of cancer progenitor cells
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isolated from patients’ malignant tissue specimens or
well-established cancer cell lines may represent a
more appropriate experimental model for the basic
cancer research and drug testing in vitro and in vivo.

Functions of cancer progenitor cells in
the cancer development
Numerous recent investigations indicated that the
most cancers may arise from the malignant transformation of multi-potent tissue-specific adult stem cells
and/or their early progenitors into cancer progenitor
cells. Furthermore, the accumulation of different
genetic and/or epigenic alterations in cancer progenitor cells during cancer progression also seems to be
associated with the occurrence of highly aggressive
cancer subtypes. However, one of the major challenges now is to determine more precisely whether
the cancers may originate in the majority of cases
from accumulating oncogenic events occurring in the
cancer progenitor cells that may lead to the generation of all the further differentiated cancer cells or
whether the more committed and differentiated cell
lineage precursors with the stem-cell-like properties
could be responsible of the initiation of certain cancer subtypes. The available experimental lines of evidence appear to corroborate the possibility that
these two processes are not exclusive and may be
dependent on the cancer subtypes [69, 90, 106–113].
In this matter, the familial genetic alterations, such as
germinal mutations may notably promote the incidence of certain cancers derived from the embryonic or adult stem cells [114–123]. For instance, it has
been proposed that the deregulation of the hedgehog signalling pathway associated with the germinal
mutations in PTCH receptor gene may lead to the
developmental defects and a pre-disposition to
develop certain tumours, such as basal cell carcinoma, medulloblastoma, meningioma, foetal rhabdomyoma as well as embryonal rhabdomyosarcoma,
which appears to originate in myogenic satellite cells
[118, 119]. Intriguingly, it has also been suggested
that the transformed cells possessing the biomarkers
and differentiating properties like embryonic hemangioblasts, which represent the putative common
embryonic precursor to both haematopoietic and
endothelial cell lineages (Fig. 1), may contribute to
the development of certain malignancies in adult life

[123, 124]. Among them, the ocular and central nervous system (CNS) hemangioblastomas, which are
highly vascular tumours that may occur in patients
with inherited von Hippel-Lindau (VHL) disease, have
been proposed to likely originate from a haematopoietic/vascular cell lineage [123, 125]. More specifically,
it has been proposed that the malignant cells that
are at the origin of the hemangioblastoma formation
within CNS in patients with VHL syndrome could represent the mesoderm-derived embryologically
arrested hemangioblasts that have persisted in
adults, and which may be further transformed under
specific conditions (Fig. 1) [123]. In addition, the
primitive neuroectodermal tumours (PNETs) including neuroblastoma, pheochromocytoma, ependymoblastoma and pineoblastoma may also originate
during the embryonic development from neuroectodermal stem cells such as neural crest stem cells
(Fig. 1) [10, 11, 121, 122, 126, 127]. For instance, it
has been reported that the immature and tumourigenic human neuroblastoma stem cells termed as
intermediate type (I-type) cells isolated from neuroblastoma tissues or cell lines were able to give rise to
the neuronal cells, melanocytes and Schwann cell
precursors that constitute the tumours [128–130].
Although further genetic studies are necessary to
confirm the possible implication of embryonic cells
in the development of certain cancers, it is noteworthy that several cancer progenitor cells derived
from adult stem cells also may re-express the
markers associated with the more primitive pluripotent embryonic stem cells. In addition to these
oncogenic changes occurring in cancer progenitor
cells, the local tumour microenvironment may also
influence their behaviour during the multiple steps
of carcinogenesis.

Influence of local tumour
microenvironment on the behaviour
of cancer progenitor cells
The functional properties of cancer progenitor cells
may be influenced through external signals mediated
by other further differentiated cancer cells and host
stromal cells including activated fibroblasts and infiltrating immune cells, such as macrophages and
endothelial cells [131–134]. Among the diverse
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growth factors, chemokines and angiogenic substances released by stromal cells, there are matrixdegrading enzymes, matrix metalloproteinases
(MMPs) and urokinase-type plasminogen activator
(uPA), stromal cell-derived factor-1 (SDF-1) acting as
CXC chemokine receptor 4 (CXCR4) ligand and vascular endothelial growth factor (VEGF) [132, 133,
135, 136]. All these soluble factors can influence, of
autocrine or paracrine manner, the tumour cell
behaviour and neovascularization process during
cancer progression. In fact, the tumour and stromal
cells may actively collaborate during each step of the
tumour formation at primary and secondary sites
in mediating the pro-angiogenic signals (VEGF
and SDF-1) that contribute to the mobilization and
recruitment of the bone-marrow (BM)-derived cells
into peripheral circulation, and their subsequent
migration to distant tumoural sites (Fig. 1) [134, 136].
Among the cells that may be attracted from BM and
peripheral circulation into primary or secondary
tumours, there are the circulating endothelial progenitor cells (EPCs) characterized by different biomarkers,
+
including CD34 or CD34 , CD133, VEGF receptor-2
(VEGFR-2), also designated as Flk-1 (foetal liver
kinase-1), SCF receptor (KIT) and CXCR4. Moreover,
the haematopoietic progenitor cells expressing
VEGFR-1 (Flt-1, fms-like tyrosine kinase) also can
participate to the new vessel formation within tumour
[131, 133–135, 137–139]. More specifically, the multipotent BM-derived EPCs possessing the stem celllike properties may migrate into peripheral circulation
and reach the tumoural sites where they can contribute to the tumour neovascularization process
(Fig. 1). The circulating EPCs can promote the
sprouting of pre-existent endothelial cells within
tumours and/or participate in the formation of new
microvasculature in differentiating into mature
+
endothelial cells with the CD34 /CD133 /VEGFR+
+
+
2 /KIT /CXCR4 phenotype that physically incorporate to new tumour microvasculature (Fig. 1) [131,
134, 137, 138, 140–142]. In regard with this, it has
been observed that the BM-derived EPCs were
recruited into the tumour site and incorporated in
lymphoma, melanoma, brain, lung, liver, pancreas,
breast and prostate tumour vessels in the mouse
models in vivo (Fig. 1) [135, 142–144]. It has been
observed that a small number of EPCs may be
detected in circulation and within tumours in the
patients diagnosed with Hodgkin’s lymphoma and
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non-small cell lung cancer (NSCLC) as well as head
and neck, thyroid, mucoepidermoid, osteogenic and
breast carcinomas [138, 145]. Although it appears
that the number of circulating EPCs that migrate to
tumour sites and contribute to tumour vascularization
is low, an enhanced number of EPCs in peripheral
circulation in NSCLC patients has been associated
with a weak response rate to antitumoural therapy
and a poor clinical behaviour and overall survival
[141]. Moreover, the possibility that a part of the
EPCs that migrates to tumour sites can give rise to
further differentiated endothelial cells within neoplasms, and thereby may be undetectable, in peripheral circulation should also be considered. Further
investigations by the engineering of specific modification in EPCs are therefore necessary to estimate
more precisely the number of EPCs that can migrate
to the tumour site as well as the amount of EPCderived-endothelial cells that are incorporated in new
tumour microvessels in diverse human cancer types.
In addition, recent studies has also revealed that the
+
EPCs including CD133 EPCs with mesenchymal
stem cell (MSC)-like characteristics and MSCs could
also reside within the specific niches in certain normal
human tissues [146–148]. Interestingly, the resident
+
CD133 renal progenitor cells, which are committed
to differentiate into endothelial cells, were able to
form the new vessels in the presence of tumourderived growth factors, and thereby can promote the
tumour growth established by co-transplanted renal
carcinoma cells in SCID mice in vivo [148]. Moreover,
the injection of BM-derived human Flk+/CD34- MSCs
as well as the differentiated human endothelial cells
into severe SCID mice engrafted with human malignant melanoma, resulted in their incorporation into
new tumour vessels as confirmed by an immunohistochemical analysis of the walls of murine tumour
vessels [149]. On the other hand, the circulating
VEGFR-1 positive haematopoietic progenitor cells
that migrate to tumour sites may release the growth
factors that promote the neoangiogenic process, and
thereby contribute to the stabilization of the microenvironment that favours the incorporation of EPCderived endothelial cells in tumour microvasculature
[134, 138, 139]. The changes within the local tumour
microenvironment combined with different oncogenic
events occurring in cancer progenitor cells during
cancer progression may also lead to the occurrence
of distinct cancer subtypes.

© 2007 The Authors
Journal compilation © 2007 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

J. Cell. Mol. Med. Vol 11, No 5, 2007

Cancer types originating from
cancer progenitor cells
New concepts of the heterogeneity of
cancers derived from distinct cancer
progenitor cells
According to the hierarchical organization model of
carcinogenesis, the leukaemic or tumourigenic cancer progenitor cells with unlimited potential for selfrenewal and altered differentiating capacity are considered to be able to generate the total cancer cell
mass of further differentiated progenies that constitutes the leukaemia or tumour [16, 39, 40, 48, 57, 65,
69, 112, 150–154]. Based on this cancer progenitor
cell concept, it is likely that the differences between
the phenotypic and functional properties of cancer
progenitor cells from which a cancer originates may
be at the basis of the heterogeneity of cancers [13,
16, 39, 40, 42, 49, 64, 73, 77, 155]. More specifically, the differentiating potential of cancer progenitor
cells from which a cancer originates may corroborate
the differentiation status of the resulting cancer subtype. For instance, certain undifferentiated- to poorlydifferentiated cancer subtypes could arise from the
malignant transformation of primitive multi-potent
stem/progenitor cells that acquire an aberrant differentiating potential resulting in a maturation arrest at an
early stage of cell lineage differentiation [39, 152, 156].
In contrast, other moderately- to well-differentiated
cancer subtypes could derive either from multi-potent
cancer progenitor cells with a high differentiating
capacity that are able to give rise to further differentiated cancer cells or more committed differentiated
cancer progenitor cells [39, 106, 112, 113, 152, 156].
Furthermore, the differences between the specific
oncogenic events activated in cancer progenitor
cells, such as a gain of new oncogenic product
expression and/or repression of tumour suppressor
genes combined with the changes in their microenvironment during the progression from localized cancers into invasive forms may lead to the development
of distinct cancer subtypes or be responsible for the
intratumoural heterogeneity noticed for a certain cancer type [39, 40, 42, 64, 69, 72, 73, 77–81, 111, 157,
158]. More particularly, the acquisition of a more
malignant behaviour by poorly- or moderately differentiated cancer progenitor cells during the EMT program including a migratory potential may result in

highly aggressive cancer forms [39, 40, 42, 64, 72,
73, 77–81]. In support with these new concepts on
the heterogeneity of cancers, several recent lines of
evidence revealed that distinct poorly- to moderately
differentiated cancer progenitor cells with different
stem cell-like properties may be at the origin of cancer subtypes. In this regard, we describe here the
recent observations supporting the heterogeneity of
cancers derived from distinct cancer progenitor cells
with a particular emphasis on the cellular origin of
leukaemia, brain and breast cancer subtypes.

Implication of cancer progenitor cells
in bone marrow-derived cancers
Leukaemias
Leukaemias are a type of cancer that arise in the
blood-forming tissue, the BM and result in the production of a large number of immature blood cells
termed as leukaemic blasts that accumulate in the
BM and within the bloodstream, and which did not
provide the functions of normal blood cells (Fig. 1).
Several experimental lines of evidence suggested
that the leukaemias, including acute myeloid/myelogenous leukaemia (AML), acute promyelocytic
leukaemia (APL), chronic myeloid/myelogenous
leukaemia (CML), acute lymphoblastic leukaemia
(ALL) and chronic lymphocytic leukaemia (ALL) may
originate from the malignant transformation of multipotent haematopoietic stem cells (HSCs) or their
early progenies in BM into leukaemic stem cells
(LSCs) also designated as leukaemia-initiating cells
(Fig. 1) [21, 22, 69, 90, 94, 95, 108, 109, 112, 154, 159,
160]. Among the frequent malignant transforming
events occurring in HSCs or their more committed
progenitors, there are the gene re-arrangements
leading to the generation of chimeric fusion oncoproteins and aberrant activation of diverse haematopoietic growth factor and cytokine signalling cascades
involved in the stringent regulation of self-renewal
and/or differentiation of HSCs, such as hedgehog,
Wnt/b-catenin, Notch, KIT and/or FMS-like tyrosine
kinase 3 (FLT3) pathways [48, 58, 108, 109, 150,
161–165]. Hence, the generation of LSCs, which
possess a self-renewal capacity and aberrant differentiating potential, can give rise to a heterogeneous
population of leukaemic blasts containing different
haematopoietic cell lineage precursors and further
differentiated cells that vary with the leukaemia subtype
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(Fig. 1) [65, 90, 108, 112]. Especially, the accumulating
genetic alterations including gene translocations
and/or mutations in CD34- or CD34+/CD38-/LIN- primitive HSCs or their early progenitors may result in the
cell sub-populations that display strong repopulating
activity and leukaemic-initiating-capacity in non-obese
diabetic (NOD)/SCID mice in vivo [90, 94, 166]. In this
matter, since it has been observed that the primitive
CD342 HSCs can give rise to CD34+ cells in animal
models in vivo, it is therefore likely that these two HSC
sub-populations may initiate certain types of
leukaemia under specific conditions [94, 95, 167].
The specific chromosomal translocations generating different fusion oncoproteins, such as TEL-AML1,
MLL-ENL, MN1-TEL and AML1-ETO and mutations
in the genes encoding transcriptional factors such as
Spi-1/PU.1 that are involved in regulation of the differentiation of haematopoietic progenitor cells may
notably inhibit their differentiation into mature
myeloid or lymphoid cells, and hence contribute to
the induction and progression of certain AML or ALL
subtypes [1, 153, 154, 168–172]. Among the initiating events associated with APL which is an AML subtype, there is a gene re-arrangement involving the
retinoic acid receptor-a gene (RAR-a) with the
promyelocytic leukaemia gene (PML), t(15;17) chromosomal translocation that generates the PML-RAR-a
fusion protein. PML-RAR-a oncoprotein may induce
an arrest of granulopoiesis concomitant with the accumulation of immature granulocytes designated as
promyelocytes [1]. Additional molecular oncogenic
events that frequently occur during leukaemogenesis
include the activating mutations in K- and N-Ras and
the members of class III receptor tyrosine kinase family, such as FLT3, KIT and PDGFR as well as tumour
suppressor gene p53 mutations and enhanced expression of Bcl-2 and Wilms tumour gene product (WT1) [1,
161, 170, 172]. These events may enhance the proliferation and/or inhibit the apoptosis in AML or ALL cells,
and thereby promote the risk of relapse [1, 161, 170,
172]. Importantly, it has also been noted that the occurrence of one transforming event that leads to an arrest
of the differentiation combined with another event inducing a proliferative effect in haematopoietic progenitor
cells may co-operate to induce the more malignant
leukaemia subtypes [1, 170, 173].
Accumulating evidence has indicated that certain
leukaemia subtypes could originate from additional
genetic and/or epigenic alterations occurring in the
intermediate haematopoietic progenitor cells, the
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pre-cancerous-LSCs (pre-LSCs) also designated as
pre-cancerous stem cells (p-CSCs) (Fig. 1) [106,
112, 113]. The pre-LSCs, which may derive from
more primitive HSCs, could possess a more limited
self-renewal and multi-potent differentiating ability. In
support with this, it has been noted that the
+
CD34 /CD38 /LIN LSCs in the most AMLs did not
express the Thy-1 surface marker like normal Thy-1+
HSCs, suggesting that these leukaemia types could
be accompanied either by the mutations leading to
the down-regulation of its expression during the
+
malignant transformation of primitive Thy-1 HSCs,
or derived from more committed leukaemic progenitor cells (Fig. 1) [90, 106, 112]. For instance, the
analyses of BM cells from AML patients showing
long-term remission after chemotherapeutic treatment, alone or combined with autologous mobilized
blood transplantation (MBT), have revealed the persistence of AML-ETO chromosomal translocation in
+
Thy-1 HSCs [106]. This suggests that this genetic
alteration may be insufficient to cause the cancer initiation. In contrast, the same patient harboured a
population of Thy-1 LSCs at diagnosis corroborating
the fact that this cancer subtype may have arisen
from the additional oncogenic events in more differentiated leukaemic progenitor cells [106]. The single
clones of p-CSCs (pre-LSCs) with CD45 /KIT /Sca-1
high
/LIN /CD44
phenotype, which have been established from the spleen of a mouse with dendritic
cell-like leukaemia, also retained an incomplete
multi-potency and can differentiate into non-malignant or malignant cells depending on their microenvironment [113]. The malignant transformation of
pre-LSCs was associated with the up-regulation of KIT
and Sca-1, suggesting that pre-LSCs may represent
a cell population with an intermediate phenotype
between the normal HSCs and LSCs (Fig. 1) [113].
Additionally, further oncogenic events in LSCs during
cancer progression, as observed for the cancer progenitor cells during EMT in solid tumours, may also
be accompanied by the acquisition of more malignant phenotypes [174]. For instance, during the initial
chronic phase of CML, a t(9;22) BCR-ABL chromosomal translocation resulting in a shortened chromo+
some 22, designated the Philadelphia (Ph ) chromosome occurs in the HSCs and generates the
chimeric BCR-ABL fusion oncoprotein with an
enhanced constitutive tyrosine kinase activity in
CML-LSCs [108, 175]. Moreover, the initial phase of
CML may be accompanied by the overexpression of
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Bcl-2 and/or decreased Jun B expression [108, 175].
These molecular events may enhance the rate of
growth factor-independent proliferation and reduce
apoptotic signals in haematopoietic progenitor cells
[174]. This initial chronic phase is followed by an
accelerated phase driven by the occurrence of further oncogenic transformation of LSCs leading ulti+
mately to the Ph B cell-ALL and the terminal stage
of the disease designated as blast-crisis (Bc)-CML
[108, 164, 175]. More specifically, the late-stage BcCML is accompanied by an expansion of granulocyte-macrophage progenitors (GMPs) expressing an
enhanced level of b-catenin whose oncogenic event
appears to be associated with an enhanced selfrenewal capacity and leukaemic potential of human
GMPs [108, 109]. On the other hand, it has also been
observed that the BCR-ABL transduction in mouse
committed myeloid progenitors does not induce their
malignant transformation in vitro whereas MOZ-TIF2
or MLL-ENL fusion proteins were transforming for
both mouse HSCs and their more committed myeloid
progenitors [107, 108, 110]. BCR-ABL-transduced
mouse committed myeloid progenitors also did not
generate an AML in animal model in vivo while MOZTIF2 or MLL-ENL-transduced-mouse myeloid progenitors were able to give rise to an AML in irradiated mouse in vivo after serial transplantations [107,
108, 110]. This suggests then that only certain types
of genetic alterations may contribute to the malignant
transformation of HSCs and/or the more committed
haematopoietic cells during leukaemia initiation
and progression.
Despite the initial implication of the primitive HSCs
and/or their early progeny (pre-LSCs) in the occurrence of the most the leukaemias, these observations suggest that the loss of the multi-potent or bipotent differentiating potential of LSCs may occur at an
early or later stage of the disease depending on the
oncogenic events occurring in the malignant cells
during cancer development. Particularly, the fact that
certain more committed haematopoietic cells may
acquire a more malignant phenotype, including an
enhanced self-renewal capacity during the cancer
progression, underlines the importance of also considering their implication for a more appropriate
therapeutic intervention. Further investigations
on the genetic/epigenic alterations occurring in
primitive human HSCs and their early progenies versus the more committed progenitor cells should

establish more precisely the molecular oncogenic
events associated with each particular case of
leukaemias.

Sarcomas
Adult BM also constitutes a homing site for several
other types of non-haematopoietic multi-potent stem
cells including EPCs and mesenchymal stem/progenitor cells (MSCs also designated MPCs) which
provide the specific functions (Fig. 1) [176]. For
instance, MSCs can give rise to diverse mature cell
lineages, such as adipocytes, chondrocytes and
osteocytes. Several lines of evidence have revealed
that the bone sarcomas, which are among the most
aggressive mesenchymal malignancies in childhood
and young adults, may originate from the malignant
transformation of primitive stem cell-like MSCs [114,
115]. More specifically, the osteoblastic sarcoma,
which is the most common type of primary bone cancer, may result in distant metastases to lungs [114,
115]. The germinal mutations in retinoblastoma (Rb)
and p53 tumour suppressor genes may notably promote the incidence of osteoblastic sarcoma
[114–117]. Since MSCs are the bone-forming
osteogenic progenitor cells, they may then represent
the putative BM adult stem cells that may be at the
origin of osteoblastic sarcoma initiation. In regard
with this, it has been reported that a small population
of bone sarcoma cells that are able to form the sarcospheres in culture expressed several markers of
MSCs (Stro-1, CD105 and CD4) as well as the
pluripotent embryonic cells (Oct-3/4 and Nanog)
[177]. This supports the potential implication of
MSCs in bone sarcoma development. More recently,
it has been observed that the cultured murine MSC
co-infused with BM into irradiated allogeneic host
could drive the development of foci of sarcoma in the
lungs and extremities in certain mice in vivo [178].
The infusion of MSC-derived sarcoma cells having a
cytogenetic profile comparable to human sarcoma
also resulted in the malignant lesions in secondary
recipients [178]. Additionally, Ewing’s sarcoma,
which is a member of Ewing’s family tumours (EFTs),
and the second most common solid bone and soft
tissue malignancy of childhood and young adults,
also appears to originate from MSCs [179]. The EFTs
are generally associated with the occurrence of a
chromosomal translocation that involves the fusion of
a 5' segment of the EWS gene with a 3' segment of
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the ETS transcription factor family gene FLI-1, given
the EWS-FLI-1 fusion protein. EWS-FLI-1 oncoprotein acts as an aberrant transcriptional activator and
contributes to tumour development. In support with
this, it has been shown that EWS-FLI-1 can transform the primary BM MSCs and generate tumours in
animal models in vivo showing the phenotypic characteristics that resemble Ewing’s sarcoma [179].

Implication of cancer progenitor cells
in paediatric and adult brain tumours
Primary malignant CNS tumours are the most frequent forms of solid malignant tumours diagnosed in
children and the glioblastoma multiformes (GBMs)
represent one of the more frequent aggressive
tumour types in adults [7, 11, 15, 29]. The cellular origin of paediatric and adult brain tumour types has not
yet been precisely established. The paediatric brain
tumours constitute a diverse group in terms of their
localization, prognosis and response to various therapeutic treatments relative to adult brain tumours
(Fig. 1) [10, 11, 29, 126, 127]. Gliomas, which are the
most common malignant primary brain tumours,
include astrocytomas (grade I slow-growing pilocytic
astrocytomas, grade II astrocytomas, grade III
anaplastic astrocytomas and grade IV GBMs), oligodendrogliomas, ependymomas and mixed gliomas,
which may contain the astrocytes, oligodendrocytes
and/or ependymal cell-like cells in different proportions
(Fig. 1) [7,15]. Several recent lines of evidence support the concept that certain brain cancers including
medulloblastomas, astrocytomas, GBMs, oligodendrogliomas and ependymomas could derive from the
malignant transformation of neural stem cells (NSCs)
or more restricted-neuronal and glial cell lineage precursors into brain cancer progenitor cells also designated as brain tumour stem cells (BTSCs) [15, 41,
52, 66, 67, 72, 73, 82, 180–182]. BTSCs could possess a self-renewal capacity but showed an abnormal ability to differentiate (Fig. 1). More specifically,
the infratentorial medulloblastomas, which are the
most common brain tumours diagnosed in childhood,
may originate either from NSCs within the ventricular
zone germinal layer or neuronal progenitors designated as cerebellar granule cell precursors (GCPs)
located in the external granular layer within the cerebellum (Fig. 1) [37, 127, 157, 158]. Aberrant activation of SHH pathway (SHH/PTCH/GLI), which is rec994

ognized to triggering normal growth of the cerebellum in the foetus, induced through the mutations in
patched receptor (PTCH), smoothened (SMO) or
Sfu, may notably contribute to uncontrolled growth of
GCPs in childhood and young children, and thereby
induce the medulloblastoma formation [37, 41, 62,
111, 127, 157,158, 183]. The p53 inactivation or sustained activation of Wnt/b-catenin pathway may also
result in an increased expression of downstream
oncogenic gene products that contribute to development of certain human medulloblastoma subtypes
[41, 111, 157, 158]. In addition, the data from a
recent study have revealed that the pilocytic astrocytomas and ependymomas arising in the supratentorial
(cortex and sub-cortex) versus infratentorial (cerebellum and brainstem) regions of the brain show specific genetic signatures, which were also detected in
NSCs localized in these regions [184]. This suggests
then that these brain tumours may derive from the
malignant transformation of a common precursor
that possesses different gene-expression patterns
depending on its brain localization. Interestingly the
+
+
tumourigenic CD133 /nestin BTSCs isolated from
ependymomas display a phenotype resembling to
radial glia-like cells, which are the neuronal precursor
cells that may give rise to mature ependymal cells
lining membrane of brain ventricles (Fig. 1) [92]. This
observation supports the fact that certain ependymoma subtypes may derive from the malignant transformation of radial glia-like cells. Similarly, the secondary or progressive GBMs may also arise from the
malignant transformation of NSCs into BTSCs that
give rise to a heterogeneous population of further differentiated cancer cells (Fig. 1) [41, 64]. The secondary GBMs, which develop slowly from low-grade
tumours, are often accompanied by the p53 tumour
suppressor gene mutations. In this matter, it has
been observed that the inactivation both of p53 and
neurofibromatosis type 1 (NF1), which is a tumour
suppressor gene that is involved in negative regulation
of Ras pathway, may co-operate to induce the development of malignant astrocytomas from early presymptomatic lesions within sub-ventricular zone containing NSCs in animal model in vivo [185]. In contrast,
other subgroup of aggressive primary GBM tumours,
which progress rapidly without evidence of a transitory step of lower grade tumour, are frequently accompanied by the overexpression of EGFR and acquisition of mesenchymal properties by cancer progenitor
cells [41, 64, 72, 73]. The results from a recent study
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have also revealed that an inhibition of the nuclear
co-repressor (N-CoR) of astroglial differentiation may
contribute to de novo GBM development in mice suggesting that this molecular event may occur in certain
GBM tumours in human [182].
In addition, the isolation of CD133/nestin positivetumour cells from patients’ malignant tissues has
revealed that these primitive cancer progenitor cells
can give rise in vitro and in vivo to different neural cell
lineages, including neuron and glial cell-like cells
(astrocytes, oligodendrocytes and ependymal cells),
but in different proportion in respect to the normal
NSCs [15, 41, 52, 66, 67, 72, 73, 82]. For instance,
it has been observed that the neurospheres
established from the paediatric medulloblastomas,
astrocytomas and GBMs were able to differentiate
majoritarly ex vitro and in vivo into cells expressing
the neural markers of original tumour cell phenotype,
including the neuronal (b-III tubulin) and astrocytic
GFAP markers [66, 67, 82]. Similarly, the multi-potent
neurosphere-like clusters isolated from adult primary
GBMs can also give rise to further differentiated progenitors expressing the specific markers to three
neural cell lineages including neurons (b-III tubulin),
astrocytes (GFAP) and/or oligodendrocytes (myelin
or galactocerebroside) ex vitro and in vivo resembling to the cellular heterogeneity characterizing the
initial GBMs [72, 73]. An immunohistochemical
analysis of brain tissue specimens from astrocytomas of different grades has also revealed that
the number of tumour cells expressing a NSC-like
phenotype (doublecortin, b-III-tubulin, collapsing
response-mediated protein-4 [CRMP-4/TUC-4] and
nestin) and proliferation marker (Ki67 antigen), was
increased in high-grade astrocytomas including
GBMs relative to low-grade neoplasms [186]. This
suggests then that a high proliferative capacity of
BTSCs could be related with the occurrence of highly aggressive tumours. In regard with this, it has been
observed that the co-injection of primary human
+
endothelial cells with CD133 BTSCs from primary
medulloblastomas in the cerebral cortex of immunocompromised mice, markedly increased the tumour
+
growth derived from CD133 cells in vivo (Fig. 1)
[187]. Based on this observation, it has been proposed that the perivascular niche of self-renewing
BTSCs could assume an important role for their
expansion during cancer development [187]. In addition, the results from a recent study revealed that certain primary glioblastoma subtypes may also derived

from a small sub-population of CD133 tumour cells
with stem cell-like properties and showing a distinct
+
gene expression pattern relative to CD133 cancer
stem/progenitor cells [188]. Hence, since these
observations suggest that different cancer stem/progenitor cells may be at origin from certain brain cancer
subtypes, further investigations are then necessary to
establish more precisely their specific properties and
sensitivity to therapeutic treatments.

Implication of cancer progenitor cells
in other cancer types
The isolation of cancer progenitor cells with the stem
cell-like properties from diverse solid tumour specimens and cancer cell lines also supports the fact that
melanoma, skin, head and neck, thyroid, cervix,
lung, liver, breast, ovary, prostate, pancreas, gastrointestinal and retinal cancers may arise from the
malignant transformation of tissue-specific adult
stem cells and/or their early progenies (Table 1, 2)
[39, 40, 47, 49, 50, 54, 59, 61, 65, 68, 70, 71, 75, 76,
80, 83–87, 96, 98–105, 189]. Particularly, the re-activation of distinct growth factor signalling including
EGFR, hedgehog, Wnt/b-catenin, Notch and/or integrin
pathways, which frequently occurs in cancer progenitor cells during the cancer initiation and EMT program, may lead to different cancer subtypes
(Fig. 1, 2) [13, 31, 35–37, 39, 40, 42, 49, 54–57,
59–62, 64, 102, 190, 191]. For instance, the occurrence of different malignant transforming events in
breast stem cells during cancer initiation and/or
accumulating of distinct genetic/epigenic alterations
in breast cancer progenitor cells and/or their early
progenies during cancer progression may result in
the formation of different breast cancer subtypes [39,
42, 47, 56, 60, 68, 75, 77, 190, 192–196]. It has been
observed that the targeted expression of stabilized b
-catenin in the basal epithelial cells of mouse mammary epithelium resulted in an enhanced proliferation
of basal-type cell-like progenitor cells possessing an
abnormal differentiation potential, whose oncogenic
event led to development of invasive basal-type carcinomas [192]. Based on the gene expression signatures detected in distinct breast cancers including the
expression levels of cytokeratin 5/6 (CK5/6),
erbB2/HER-2/Neu, estrogen receptor (ERa) and/or
progesterone receptor (PR), the invasive breast cancers have been classified at least five subtypes [8,
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14, 156, 197–201]. Among them, there are the basallike (CK5/6+, ERa-, PR-, erbB2-/low, EGFR+, vimentin+
and KIT+); erbB2+ overexpressing (ERa- and PR-;
luminal A (ERa+ and/or PR+ and erbB2-); luminal B
+
+
+
(ERa and/or PR and erbB2 ) and normal breastcancer subtype (high expression of normal epithelium genes and low expression of luminal epithelial
gene products) [8, 14, 152, 197–201]. It has been
observed that the ERa-negative breast cancer subtypes including the basal-like breast cancers and
erbB2-overexpressing breast cancers, which are
among the most aggressive breast cancer forms
diagnosed, are generally associated with a poor
prognosis and survival of patients to current clinical
therapies [197–200, 202, 203]. Despite the activation
of estrogen-ERa signalling cascade may contribute
+
to ERa -epithelial cell proliferation, it has been
observed that the ovariectomy had no effect on the
+
size of the mouse mammary EGFR stem cellenriched population, which did not express ERa, PR
or erbB2 [204, 205]. Moreover, the mouse ERabreast cancer cells may express a lower level of E+
cadherin than the ERa breast cancer cells, and
therefore they can display a higher migratory capacity [206]. Although further studies are essential to
+
confirm the implication of estrogens/ERa cascade
for the proliferation of human ERa breast cancer
progenitor cells, it appears likely that the different
breast cancer subtypes may respond differently to
the therapies consisting to targeting ERa, erbB2
and/or EGFR [202, 203, 207]. In this matter, we are
reporting the specific functional properties of cancer
progenitor cells that may contribute to their resistance to current therapies.

Novel cancer therapies by molecular
targeting of cancer progenitor
cells and their microenvironment
New concepts on the functions of cancer
progenitor cells in the resistance to
current cancer therapies
Accumulating evidence revealed that the intrinsic or
acquired resistance of poorly differentiated and
leukaemic or tumourigenic cancer progenitor cells to
current clinical therapies may lead to their persist996

ence in primary and secondary neoplasms after
treatments, and thereby contribute to cancer recurrence [13, 16, 35, 39, 40, 55, 56, 59, 62, 64, 71, 78,
81, 88, 89, 155]. In this regard, certain ABC multi-drug
efflux transporters including P-glycoprotein (P-gp)
encoded by the MDR1 (ABCB1) gene, the multi-drug
resistance-associated protein 1 (MRP1) and breast
cancer resistance protein-1 (mouse BCRP-1)/human
ABCG2/MXR gene products are frequently overexpressed in cancer progenitor cells [16, 35, 46, 88, 89,
95, 208]. Since the SP cells, which possess the stem
cell-like properties, generally express higher levels of
ABC multi-drug efflux pump(s) than the non-SP cells,
it is likely that this phenotype may be also related to
the intrinsic resistance of certain cancer progenitor
cells to chemotherapeutic treatments. In support with
this, several data have revealed that the SP cells
from malignant tissues or cancer cell lines were more
resistant than the non-SP cells to the chemotherapeutic drugs, and the enhanced drug efflux in the SP
cells was associated with a high rate of survival [54,
80, 88, 89, 209]. For instance, the SP cells isolated
from HuH7 hepatocellular cancer cells, which
expressed the high levels of ABCG2 and ABCB1
multi-drug efflux pumps as well as carcinoembryonic
antigen-related cell adhesion molecule (CEACAM6),
which may contribute to gemcitabine chemoresistance, displayed a greater resistance to doxorubicin,
5-fluorouracil (5-Fu) and gemcitabine treatment than
the non-SP fraction [80, 210]. Similarly, the SP cells
from the mouse ovarian MOVCAR 7 cancer cell line,
which express the BCRP-1 gene product, were also
more resistant to the anti-proliferative effect of doxorubicin which acts as a substrate of BCRP-1 efflux
pump than the non-SP fraction [98]. The ABCG2
gene product overexpression in mitoxantrone-resistant MCF-7/MitoR breast cancer cells also resulted in
a substantial decrease of intracellular accumulation
of Hoechst 33342 dye and enhanced the number of
SP cells with an acquired multi-drug resistance phenotype as compared to parental MCF-7 cell line
[208]. Thus, the selection of multi-drug-resistant cancer progenitor cells by continuous drug treatment
may result in an increase of their proportion in total
cancer cell mass, and thereby contribute to the cancer progression to highly aggressive cancers and
disease relapse [54]. In addition, the enhanced
expression/activation of many growth factors and
anti-apoptotic signalling elements may also
contribute to the drug resistance and survival of
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cancer progenitor cells [13, 16, 30, 31, 35–37,
39–42, 46, 54–61, 78, 89]. For instance, many
changes in the apoptotic signalling elements have
been observed in the chemotherapy resistant ex
vivo selected ‘survivor cell’ population which was
enriched for CD34+ LSCs [211]. Similarly, CD133+
BTSCs isolated from primary cell lines established
from glioblastoma patients, which expressed higher
levels of CD90, CD44, CXCR4, Nestin, Msi1 and
MELK relative to CD133 cancer cells, were also resistant to diverse chemotherapeutic drugs such as temozolomide, carboplatin, etoposide and paclitaxel [78].
On the other hand, the cancer stem/progenitor cell
model of carcinogenesis may also explain the differences of response of distinct cancer subtypes to current therapies as well as the dormancy phenomenon
and disease relapse, which may be associated with
a higher resistance of cancer progenitor cells to conventional therapies under specific conditions prevalent in primary and/or secondary neoplasms relative
to their further differentiated progeny [14, 25, 39, 40,
46, 79, 207, 212]. Importantly, it has been observed
-/low
mammosphere cell cultures
that the CD44/CD24
established from human MCF-7 breast cancer cells
were more resistant to radiation than the adherent
breast cancer cell fraction and that their number was
+
enhanced after radiotherapy [213]. Similarly, Sca-1
multi-potent progenitor cells from an immortalized
COMMA-Db-geo murine mammary gland cell line
expressing a high Wnt/b-catenin level were also
resistant to radiation at a clinically relevant dose
+
[212]. Moreover, the CD133 breast cancer stem cell
population from glioblastomas was also enriched
after ionizing radiation treatment whose radioresistance phenomenon may be associated with a
preferential activation of the DNA damage checkpoint response concomitant with an increase in DNA
2
repair capacity relative to the CD133 fraction [79].
Additionally, since most of the solid tumours are molecularly heterogeneous and distinct cancer cells may
possess specific hyper-activated intracellular signalling cascades, it appears that the targeting of distinct oncogenic pathways may represent a more
effective strategy to eradicate the total cancer cell
population in certain aggressive and recurrent cancers.
Consistent with this, it has been observed that the
undifferentiated-type areas of heterogeneous gastric
tumours display a higher GLI1 nuclear immunostaining than the differentiated-type areas suggesting that

the undifferentiated gastric cancer subtype could be
more sensitive to the agents targeting hedgehog
cascade [214]. In analogy with the BM-resident
HSCs which possess long-term in vivo re-populating
abilities and are mainly under a quiescent state, the
primitive quiescent LSCs may also be more resistant
than diving LSCs to the agents, such as 5-FU or imatinib mesylate that principally act on the proliferative
cells (Fig. 1) [78, 81]. Hence, all these stem cell-like
properties attributed to cancer progenitor cells may
provide them with a higher resistance to current cancer therapies, and thereby constitute a substantial
obstacle to the successful treatment of cancer
patients. Together, these observations underline
then the critical importance of targeting the cancer
progenitor cells and their early progenies as well as
their local microenvironment in the earlier stages of
cancer treatment to counteract the rapid progression of certain cancer types and prevent the
metastatic spread at distant sites. In regard with
this, we describe here the new cancer therapeutic
strategies based on targeting of different oncogenic cascades activated in highly leukaemic or
tumourigenic cancer progenitor cells, and which
must now be considered for improving the current
therapeutic treatments.

New combination therapies against the
aggressive and recurrent cancers
Targeting cancer progenitor cells
The simultaneous blockade of several oncogenic cascades activated in cancer progenitor cells during cancer progression may be essential for improving the
current clinical treatments against high-risk, metastatic or relapsed leukaemias, multiple myelomas and
numerous solid cancers, including neuroblastomas,
medulloblastomas, GBMs and skin, lung, head and
neck, breast, ovary, prostate, liver, pancreas and gastrointestinal cancers [1, 12, 13, 15–17, 30, 31, 35–42,
55–57, 59–62, 163, 164, 190, 191, 214, 215]. Among
them, the molecular targeting of diverse developmental cascades including hedgehog, Wnt/b-catenin,
Notch, EGFR, PDGFR and KIT pathways and/or
oncogenic signalling elements (telomerase, Src, ABL,
PI3K/Akt, MYC, NF-kB and survivin) which assume a
critical function in regulating the self-renewal, survival
and invasion of cancer progenitor cells as well as in
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Table 3 Specific inhibitors of growth factor cascades and signaling elements involved in sustained growth, survival
and/or drug resistance of cancer progenitor cells and angiogenic process
Targeted signaling element

Name of inhibitor

EGFR family member inhibitor
Anti-EGFR (erbB1) antibody

mAb-C225, IMC-C225

Anti-EGF antibody

ABX-EGF

EGFR-TKI

Gefitinib, erlotinib, AG1478, EKB-569

Anti-erbB2 antibody

Trastuzumab

EGFR-erbB2-TKI

PKI-166, TAK165, GW572017 (lapatinib)

erbB1/erbB2/erbB3/erbB4-TKI

CI1033

Other growth factor signaling inhibitor
Hedgehog

SMO inhibitor cyclopamine, anti-SHH antibody

Wnt/b-catenin
Notch

Anti-Wnt antibody, WIF-1
g-secretase inhibitor DAPT, GSI-18
Imatinib mesylate (STI571)

PDGFR/KIT/ABL-TKI
PDGFRb/FLT3
VEGF

Sorafenib

VEGFR

Anti-VEGFR antibody

VEGFR1,2 and 3

CEP-7055, AZD2171

VEGFR1,2,3 /PDGFRb/KIT
Signaling element inhibitor

AMG 706, Vatalanib (PTK787/ZK 222584)

Telomerase

Telomerase template antagonist

MYC

As-MYC

Bcl-2

ABT-737

PI3K

LY294002, rapamycin, CCI-779

NF-kB inhibitor
Src-family and ABL-TKI

IkBa inhibitor, sulfasalazine, bortezomib (PS-341)
PD180970

Src-family-TKI

CGP-76030

Anti-VEGF antibody (bevacizumab), As-VEGF

Fusion oncoprotein inhibitor
BCR-ABL

Imatinib mesylate (STI571), dasatinib (BMS-354825), nilotinib
Imatinib mesylate (STI571)

FIP1L1-PDGFRa
PML-RAR-a
Drug transporter inhibitor
ABC multidrug efflux transporter
MDR1/ABCB1/P-gp

All-trans retinoic acid

MRP1/ABCC1

MS-209

ABCG2/BCRP

Gefitinib, CI1033, tamoxifen derivatives, cyclopamine

Organic cation intracellular transporter Oct-1

Prazosin

MS-209, gefitinib, CI1033, tamoxifen, cyclopamine

DAPT, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; EGFR, epidermal growth factor receptor;
KIT, stem cell factor (SCF) receptor; GSI-18, [11-endo]-N-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8]annulen-11ylthiophene-2-sulfonamide; MDR1, multidrug resistance 1; MRP1, multidrug resistance-associated protein 1; MRP2,
multidrug resistance-associated protein 2; NF-kB, nuclear factor-kB; PDGFR, platelet-derived growth factor receptor; Pgp, P-glycoprotein; PI3K, phosphatidylinositide-3'-kinase; TKI, tyrosine kinase inhibitor; VEGF, vascular epithelial growth
factor; VEGFR, vascular epithelial growth factor receptor; WIF-1, Wingless inhibitory factor-1; Wnt, Wingless ligand
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drug resistance and disease relapse, is of therapeutic
interest [1, 12, 13, 16, 17, 26, 30, 31, 35–45, 49,
55–59, 61, 62, 64, 78, 102, 164, 190, 191, 214, 216,
217]. In this matter, one of the major significant
advances in cancer therapeutics over the few last
years has been the development of a number of novel
anti-carcinogenic agents, including the antibodies
and small chemical molecules such as the protein
tyrosine kinase inhibitors (TKIs) (Table 3) [12, 13, 16,
17, 24, 26, 30, 36, 37, 39, 40, 57, 216, 218–220].
These pharmacological agents, which target one or
several oncogenic products involved in the malignant
transformation of human cells, may be used alone or
in combination with conventional therapeutic treatments against certain aggressive cancers. For
instance, certain anti-carcinogenic agents may
induce the apoptotic death and/or a differentiating
effect on primitive cancer-initiating cells, and thereby
may constitute the useful tools for the development of
more effective cancer therapies [13, 16, 26, 30, 35,
37, 39–41, 48, 55, 57, 59, 150, 215, 221]. The combination of high-dose chemotherapy or radiation with
autologous or allogenic stem cell transplantation also
represent another alternative for the patients diagnosed with advanced and refractory/relapsed
leukaemias, multiple myeloma, lymphomas and sarcoma as well as brain, lung, breast, kidney, ovary and
colorectal cancers [13, 16, 222–224].
Among the current clinical targeted therapies, the
use of imatinib mesylate, which is a TKI targeting
+
BCR-ABL oncoprotein, has provoked great interest
based on its high efficacy and safe profile and successful use for the first-line clinical treatment of
+
+
patients with BCR-ABL (Ph ) CMLs in initial chronic
phase [16, 24, 27, 28, 33]. Moreover, imatinib mesylate may also act as a potential therapeutic agent for
+
the treatment of Ph AML, FIP1L1-PDGFRA positive
chronic eosinophilic leukaemia and gastrointestinal
stromal tumours which frequently harbour the activating mutations in KIT and PDGFRA tyrosine kinase
receptors [24, 27, 28, 33, 225]. Particularly, the inhibition of the tyrosine kinase activity of chimeric BCRABL fusion oncoprotein by imatinib mesylate may
lead to a complete cytogenetic remission after initiation treatment in the most patients diagnosed with
+
+
BCR-ABL (Ph ) CMLs [27, 28, 33]. However, the
persistence of quiescent CML-LSCs resistant to imatinib treatment as well as the progression to an
advanced and late-stage CML disease, accelerated
phase or terminal blast crisis phase, is often accom-

panied by acquisition of a more malignant transformed phenotype by LSCs and disease relapse [27,
28, 32–34, 81, 226–228]. The mutations in BCL-ABL
and other independent BCR-ABL mechanisms, such
as the up-regulation of Scr-related LYN kinase, SHH,
Wnt/b-catenin,
anti-apoptotic
factor
Bcl-2,
MDR1/ABCB1 and ABCG2/BCRP muli-drug efflux
transporters and/or cellular organic cation transporter Oct-1 involved in the uptake of imatinib may
contribute to the CML recurrence [16, 27, 28, 32–34,
81, 164, 226–228]. Therefore, the combined use of
distinct anti-leukaemic agents that are able to inhibit
diverse oncogenic cascades that are activated in
LSCs is of particular interest for overcoming imatinib
resistance in the refractory/relapsed CML patients.
Among them, there are the inhibitors of BCR-ABL
(dasatinib and nilotinib), Scr-related LYN kinase
(PD180970), anti-apoptotic factor Bcl-2 (ABT-737) or
Oct-1 transporter (prazosin) which may be used
alone or in combination with imatinib mesylate and/or
other cytotoxic drugs, such as interferon-a [27, 28,
34, 175, 227, 229–232]. Recently, it has also been
+
observed that the exposure of quiescent BCR-ABL
CML-LSCs to the growth factors such as granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating factor (GMCSF) may decrease the number of non-dividing
+
BCR-ABL CML-LSCs, and thereby could also constitute an alternative strategy for improving the imatinib mesylate-based therapies [233, 234]. Similarly,
the current treatment for APL, which consists of the
combined use of all-trans retinoic acid (ATRA) and
anthracycline-based chemotherapy, generally results
in a high rate of complete cytogenetic remission
(about 90%) and an overall survival rate of 80% in
the initial phase. Certain patients with high-risk APL
may, however, relapse [21, 23]. In these cases, the
efficacy of clinical treatment of high-risk and relapsed
+
PML-RAR APL may also be improved by the combined
used of a differentiating agent, ATRA plus cytotoxic
drugs such as arsenic trioxide that may co-operate to
+
eradicate the total population of PML-RAR APLLSCs [21–23]. Additionally, it has also been observed
that the use of an inhibitor of g-secretase (DAPT), a
protease that is involved in the activation of Notch
receptor-mediated intracellular signalling by its ligand Jagged-2, which is overexpressed in the LSCs
+
from AML samples, may inhibit the growth of CD34
CD38 AML-LSC fraction in colony formation assays
in vitro [235]. The molecular mechanisms underlying
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the cytotoxic effect of DAPT on LSCs appears to be
due in an alteration of the AML-LSC fate and the
interference of this agent with the transportation of
LSCs into the stem cell-supportive microenvironmental niche [45]. Interestingly, a recent study has also
indicated that the targeting of LSCs at the origin of
certain AML subtypes by using an activating monoclonal antibody directed against the cell surfaceadhesion molecule CD44 results in a reduction of
leukaemic population in human AML-LSC cells
transplanted NOD-SCID mice in vivo as well as in the
absence of leukaemia development after subsequent
serial transplantations in other mice [236]. The
data from another study carried out on a murine
leukaemia model have also revealed that
CALM/AF10-positive AML can be propagated by a
transformed leukaemic progenitor cells, with lymphoid characteristics including CD45RA (B220)
expression and Ig DH-JH re-arrangement, which can
be targeted by antibodies that do not cross-react with
normal HSCs [237].
Interestingly, recent studies have also revealed the
possibility of using the agents targeting the EGFR,
hedgehog, Wnt/b-catenin and/or Notch cascades to
inhibit the ABC muli-drug efflux transporters and/or
eliminate the cancer progenitor cells (Fig. 2; Table 3)
[57, 89, 102, 191, 215, 238–240]. For instance, it has
been observed that the EGF treatment of human
metastatic UMSCC10B and HN12 head and neck
squamous carcinoma cell lines was accompanied by
an increase of number of the SP cells and the add of
gefitinib reduced the SP population [102]. The
cyclopamine treatment of poorly differentiated and
+
highly-tumourigenic CD44 PC3 metastatic prostate
cancer cells, which possess an intermediate phenotype
(androgen receptor negative, CK5/18), was also accompanied by a decrease of the expression levels of MDR1
and BCRP/ABCG2 suggesting that the activation of
hedgehog signalling may contribute to MDR in these
cancer cells [239]. Importantly, the continuous
cyclopamine treatment of PC3 cell-xenografts established in nude mice in vivo has also been observed
to result in apoptotic cell death and tumour regression [191]. Also, no sign of the tumour recurrence
and secondary effects on normal cells was detected
72 hrs after the cessation of treatment, suggesting
that the cancer-initiating cells may have been eliminated [191]. Similarly, it has also been reported that
the hedgehog ligand induces a clonal expansion of
multiple myeloma (MM) stem cells while cyclopamine
1000

treatment counteracts the expansion of purified MM
stem cells but has little effect on the growth of their
further differentiated malignant plasma cells [238].
The number of SP cells detected in the NCL-H929
MM cell line was also decreased after the
cyclopamine treatment [238]. Of particular therapeutic interest, cyclopamine alone also inhibited the self+
renewal ability of CD133 glioma cancer stem cell
cultures established from human GBM tumour samples in vitro, and induced an additive or synergistic
anti-proliferative and apoptotic effect at a lower concentration in combination with the current therapeutic drug, temozolomide on the gliomasphere cells
[240]. Long-term treatment of gliomasphere cells
expressing a high expression of the stemness genes
(GLI1, PTCH1, Nanog, Oct-4, SOX2, BMI1 and
PCNA) with the cyclopamine alone also killed all
these cancer stem cells in culture, and induced the
regression of glioma tumours established from the
gliomasphere cells in nude mice in vivo, without
detectable secondary effects [240]. Moreover, the
+
radioresistant property of CD133 glioblastoma stem
cells could also be reversed by using a specific
inhibitor of the CDK1 and CDK2 checkpoint kinases
[79]. Additionally, the suppressing of b-catenin
+
expression in Sca-1 multi-potent progenitor cells
from an immortalized COMMA-Db-geo murine mammary gland cell line has been observed to decrease
their self-renewal capacity [212]. The results from a
recent investigation have also indicated that the
Notch signalling blockade by using an inhibitor of g+
secretase (GSI-18) significantly reduced the CD133
cell fraction and eliminated the SP cells detected in
medulloblastoma cell mass, which express a high
Notch signalling levels [215]. Since the medulloblastoma cells treated with Notch inhibitor did not effectively form the tumour xenografts in vivo, it has been
suggested that the cancer-initiating cells have been
eradicated [215].

Targeting the local microenvironment of cancer
progenitor cells
The development of more effective antitumoural
strategies also implicates the inhibition of the neoangiogenic process which is necessary for the tumour
vascularization and growth. Many anti-angiogenic
agents that are able to interfere with the VEGFVEGFR transduction system, including the antiVEGF or VEGFR antibody, VEGFR antagonists and
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the soluble truncated form of VEGFR have been
designed and observed to effectively counteract the
tumour growth in animal models in vivo (Table 3) [30,
131, 132, 134–136, 140, 187, 241]. Particularly, it
has been observed that the targeting of VEGFRs
may be more effective than the inhibition of the single receptor to prevent and/or counteract the tumour
formation in animal models in vivo [135, 137].
Interestingly, the treatment of the mice bearing orthotopic U87 glioma cell xenografts with anti-VEGF
monoclonal antibody, bevacizumab markedly
reduced the microvasculature density and tumour
growth and this anti-angiogenic effect was also
accompanied by a decrease of the number of vessel+
+
associated self-renewing CD133 /nestin tumour
cells [187]. Based on these observations, it has been
suggested that the bevacizumab may act, at least in
part, by disrupting the vascular microenvironment
‘niche’ of BTSCs, and thereby impairs their selfrenewal capacity (Fig. 1) [187, 242]. In addition, several lines of evidence have revealed the potential
benefit of targeting the tumour-specific vascular pre+
cursor cells including the circulating VEGFR-2 +
EPCs and VEGFR-1 -PMC which may be recruited
within the activated stromal compartment in the primary and secondary neoplasms for preventing
and/or counteracting the neovascularization process
associated with tumour development (Fig. 1) [134,
136, 137, 140]. More particularly, it has been shown
that the use of BM-derived EPCs engineered to
express an anti-angiogenic gene product, a soluble
truncated form of VEGFR-2, may impair tumour
growth in vivo [140]. The identification of further specific biomarkers to the tumour-specific EPCs should
therefore help to develop the more effective anti-angiogenic treatments based on their molecular targeting.

Conclusions
Altogether, these recent investigations have revealed
that the most aggressive cancers may originate from
the malignant transformation of embryonic or adult
stem/progenitor cells into cancer progenitor cells.
The cancer progenitor cells can provide critical functions in cancer initiation and progression into
metastatic and recurrent disease states. Based on
these observations, the molecular targeting of highly
leukaemic or tumourigenic cancer progenitor cells

must be considered for improving the efficacy of the
current cancer therapies. New drug combinations targeting cancer progenitor cells have been developed
and shown to be effective against certain aggressive
cancers in the clinical settings. Additional investigations to identify the specific biomarkers and resistance mechanisms of cancer progenitor cells versus
their further differentiated malignant progenies and
their normal counterparts, adult stem cells should
lead to more effective and safe therapeutic treatments
for the most the aggressive and incurable cancers.

Future directions and perspectives
The technical advancements in the adult stem cell
biology have provided the methods to isolate and
characterize the ex vitro and in vivo properties of
cancer stem/progenitor cells. However, the evaluation of their functional properties ex vivo must be
considered with caution since multiple extrinsic factors may influence their behaviour, and more particularly, the experimental culture conditions did not
necessarily reflect their local microenvironment within
the tumours. Further investigations of cancer progenitor cells in more vigorous experimental conditions
are required, and thereby should help to elucidate
the molecular mechanisms that provide a critical role
for their uncontrolled self-renewal and/or aberrant differentiation capacity. The differences between the
specific biomarkers and functional properties of cancer progenitor cells versus their normal counterpart,
adult stem cells should notably be exploited for the
specific targeting of cancer progenitor cells, and
thereby preserve the integrity of normal tissue-specific adult stem cells. The cancer progenitor cells also
exhibit a differential gene expression pattern, as
compared to the bulk mass of further cancer cells,
and therefore a re-analyse of the oncogenic gene
products activated specifically in cancer progenitor
cells appears to be necessary. Further investigations
by using the cancer progenitor cells isolated from primary cancer patient’s malignant tissues at different
stages during the cancer progression and metastatic
disease should help to identify new biomarkers for
the development of more effective diagnostic and
prognostic methods and targeted therapies against
the aggressive and metastatic cancers. The development of new effective and safe targeted therapies by
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eradicating the total population of cancer progenitor
cells and their further differentiated progenies at the
primary and secondary neoplasms should allow us
to improve the current cancer treatments, prevent
the disease relapse and thereby induce a complete
cytogenetic remission and cure of cancer patients
in the clinics.
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